Better Therapeutics, Inc. · OTC:BTTX

Better Therapeutics — Investor Presentation (September 2022)

47 slides from Better Therapeutics's investor presentation, Sep 14, 2022

  1. Slide 1: Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases

    Exhibit 99.1 Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases SEPTEMBER 2022

  2. Slide 2: Disclaimer

    Disclaimer This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the Company“) nor any of its respective affiliates nor any of its or their control persons, off

  3. Slide 3: Contents

    The Problem Better Therapeutics Approach How our Product Works Contents BT-001 Pivotal Trial Go-to-Market Plan Investment Summary 3

  4. Slide 4: Chronic disease prevalence and healthcare spending

    % % Tn 50 86 $ 4.1 of adults in the US of healthcare dollars are spent on US National Health 2 2 have a chronic disease chronic disease maintenance 1 Expenditure in 2020 Currently available drugs treat symptoms but do not impact the root cause of disease. Most patients get worse over time despite be

  5. Slide 5: Spending more money to get worse outcomes

    We are spending more and more money to get worse and worse outcomes HYPERTENSION DIABETES US Healthcare Expenditures ($ in trillions) Americans Diagnosed with Diabetes (millions) US Healthcare Expenditures ($ in trillions) Americans Diagnosed with Hypertension (millions) $4 $4 110 30 $3 82.5 55 $2 2

  6. Slide 6: Cardiometabolic diseases progress, leading to costlier complications

    The vast majority of patients diagnosed with cardio metabolic diseases progress in their disease, leading to more costly complications and interventions over time 1 Example: Type 2 Diabetes Typical Disease Progression Additional Advanced Insulin Non-Insulin Pre-Diabetes Non-Insulin Diagnosis Comorbi

  7. Slide 7: Contents

    The Problem Better Therapeutics Approach How our Product Works Contents BT-001 Pivotal Trial Go-to-Market Plan Investment Summary 7

  8. Slide 8: Lifestyle behaviors as common root cause of chronic diseases

    Many of the most common (and costly) chronic diseases share lifestyle behaviors as a common root cause. Better Therapeutics combines medical, behavioral and digital/data science to create software based therapeutics that are designed to improve human health by targeting behavior change. 8

  9. Slide 9: Clinical guidelines highlight behavior change but no prescribable options

    CURRENT CLINICAL GUIDELINES highlight behavior change as the foundation of treatment, but physicians have no options to prescribe it Emphasize importance of behavior change Call for digital solutions to facilitate behavior change Encourage reimbursement for solutions for behavior change No digital s

  10. Slide 10: The Better Therapeutics Approach

    Next Generation Therapeutics: The Better Therapeutics Approach Developing Digital Therapeutics that are authorized by the FDA for a specific indication and have labeled claims. If authorized or cleared, patients obtain access through a physician prescription that is reimbursed via health insurance I

  11. Slide 11: Unique benefits of digital therapeutics

    Opportunity to address healthcare inequities and access Digital therapeutics can reach patients where they are and connect them to the best care despite the many barriers patients experience Real-time insights into use and efficacy enables continuous improvement promising the potential for increasin

  12. Slide 12: Pipeline of PDT products using nCBT

    We are advancing a pipeline of PDT products using nCBT to treat multiple cardiometabolic diseases Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Pivotal (BT-001) De Novo Submission & FDA Review Type 2 Diabetes Pilot Hypertension Pilot Hyperlipidemia D

  13. Slide 13: Contents

    The Problem Better Therapeutics Approach How our Product Works Contents BT-001 Pivotal Trial Go-to-Market Plan Investment Summary 13

  14. Slide 14: Cognitive Behavioral Therapy

    Cognitive Behavioral Therapy Developed in the 1960s, it is considered the gold standard for evidence-based therapy to help patients make lasting behavior changes by changing neural pathways in the brain 14

  15. Slide 15: Traditional CBT limitations

    Traditional Cognitive Behavioral Therapy (CBT) is effective at addressing the behavioral root causes of cardiometabolic diseases but has limitations Not Standardized Not Scalable Treatment plans to treat cardiometabolic Patients must commit to 8 - 20 CBT diseases with CBT are selected by individual

  16. Slide 16: Nutritional CBT delivered digitally

    We created nutritional CBT to treat the root causes of cardiometabolic diseases and designed it to be delivered digitally to make it accessible, affordable and scalable Works within the Unifies behavioral Goes far beyond the existing framework of therapy, lifestyle typical “cognitive standard medica

  17. Slide 17: Nutritional CBT delivered via physician-prescribed mobile app

    We deliver nutritional CBT using a mobile app prescribed by a physician Nutritional CBT is delivered via weekly therapy lessons, skill-building modules, and goal-setting. A treatment algorithm tailors treatment to each individual patient. Feedback is provided using a treatment score, rewards, and pr

  18. Slide 18: Cognitive Behavioral Therapy

    COGNITIVE BEHAVIORAL THERAPY Changes thoughts and beliefs so that difficult behavior changes are possible. Changes neural pathways in the brain and builds the acceptance and resilience needed to handle challenging obstacles and emotions. 18

  19. Slide 19: Lifestyle Medicine

    LIFESTYLE MEDICINE CBT creates the desire to change. Lifestyle medicine provides the “how.” Treatment Plan Guides changes in dietary behavior and physical activity, while improving medication adherence and self-monitoring. 19

  20. Slide 20: Artificial Intelligence

    ARTIFICIAL INTELLIGENCE We use AI to reveal the right treatment pace, intensity and support needed to maximize efficacy for each individual. Personalization A treatment algorithm dynamically adjusts goals to maximize treatment response, and provides a feedback loop that is designed to sustain engage

  21. Slide 21: Data collected helps patients get best outcomes

    The data we collect helps patients get the best possible treatment experience and outcomes • Visualizations of treatment progress • Monitoring of engagement and biometrics • Alerts when patients disengage from treatment to enable early intervention • Algorithms predict patient success from engagemen

  22. Slide 22: Contents

    The Problem Better Therapeutics Approach How our Product Works Contents BT-001 Pivotal Trial Go-to-Market Plan Investment Summary 22

  23. Slide 23: Randomized controlled pivotal trial in type 2 diabetes

    First in class, randomized control pivotal trial in Type 2 Diabetes BT-001 + Standard of Care Primary Endpoint Secondary Endpoint (Day 90) (Day 180) N = 325 Patients with Uncontrolled Type 2 Diabetes N = 668 Standard of Care Control Group N = 343 Mean change in Patients had longstanding type 2 Mean

  24. Slide 24: Pivotal trial design and patient population

    Nationally representative, diverse patient population Investigators mirror real-world prescribers Robust study design employed to minimize bias and set BT-001 Pivotal high comparison bar: Trial designed primarily for Control arm is Standard of Care (i.e. gold standard care), • not just treatment as

  25. Slide 25: BT-001 pivotal trial results

    BT-001 demonstrated clinically meaningful and sustained reduction in A1c over 180 days Both primary (A1c between group delta -0.4%, p<0.0001) and • secondary endpoint (A1c delta -0.3%, p=0.01) were met Significant improvements observed in BT-001 group despite use of • Pivotal Trial Results fewer dia

  26. Slide 26: BT-001 reduced A1c despite added medication in control group

    BT-001 reduced A1c despite on-study addition of more diabetes medication in the Standard of Care control group Baseline A1c D90 A1c D180 A1c 0.2 1.5x more SOC patients 0.1 increased meds prior to day 180 SOC 0 BT-001 Primary EndPoint 0.4% Delta, -0.1 p < 0.0001 Secondary EndPoint -0.2 0.3% Delta, p

  27. Slide 27: Trending change in fasting blood glucose

    Trending average change in fasting blood glucose in BT-001 group shows gradual and steady improvements, with no clear peak 27

  28. Slide 28: Fasting blood glucose trends across therapies

    Trends in fasting blood glucose in different therapies 0 -4 -8 -12 -16 -20 Baseline W4 W8 W12 W16 W20 W24 BT-001 Ferrannini E et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 tr

  29. Slide 29: Greater use associated with greater A1c reduction

    Patients who used BT-001 more had greater reduction in A1c Participants self-selected dose of nCBT. Higher dose of nCBT lessons completed associated with larger A1c improvements at 180 days Low Use of Moderate Use of High Use of Behavior Therapy Behavior Therapy Behavior Therapy < 10 lessons 10-20 l

  30. Slide 30: More BT-001 patients achieved meaningful A1c change

    1.5x more BT-001 patients achieved meaningful A1c change Significant improvements observed in BT-001 Group despite use of fewer diabetes medications ITT Population at D180 Δ = 16.1% p = 0.0004 Achieve 1% or more % 0 A1c reduction 30 (vs 17%, p=0.001) 10 20 30 34.3% 40 Achieve blood sugar % 50 contro

  31. Slide 31: Meaningful responders show large improvements at 180 days

    BT-001 Meaningful Responders show range of large improvements at 180 days Meaningful Responders” defined as 0.4% or more A1c improvement MEAN -1.3% MEDIAN 12% -1.1% 10% 8% 6% 4% 2% 0% -0.4 -0.5 -0.6 -0.7 -0.8 -0.9 -1 -1.1 -1.2 -1.3 -1.4 -1.5 -1.6 -1.7 -1.8 -1.9 -2 -2.1 -2.2 -2.3 -2.4 -2.5 -2.6 -2.7

  32. Slide 32: Safety data shows fewer adverse events

    180 Day safety data reveals significantly fewer Adverse Events BT-001 patients had statistically significant fewer AEs and Serious AEs Standard of Care BT-001 (n=343) (n=325) Subjects Events Subjects Events Number of subjects who experienced: n (%) n n (%) n An Adverse Event (AE) 188 (54.8%) 324 135

  33. Slide 33: Safety profiles of top diabetes drugs differ from BT-001

    Safety profiles of top performing diabetes drugs differ from BT-001 Adverse Reaction (>/= 5%) GLP1 SGLT2 BT-001 Pivotal Nausea Yes No No Vomiting Yes No No Diarrhea Yes No No Abdominal pain Yes No No Constipation Yes No No Female genital mycotic infections No Yes No Urinary track infections No Yes N

  34. Slide 34: Exploratory endpoints

    Exploratory Endpoints Statistically significant findings in: Data revealed statistically significant Systolic Blood Pressure • changes in multiple Weight Reduction • endpoints, Mood Scores • underscoring potential Quality of Life Scores (Physical Health-Related) • for broad-based Adverse Event and S

  35. Slide 35: Patient engagement and persistence exceeded benchmarks

    During 180 days of use, patient engagement and persistence exceeded benchmarks for consumer health & wellness apps* 5.9 81% 61 Average minutes / day NPS Score after Percentage of patients spent in app using the app at 180 days 180 days % % % % 36 38 36 35 Healthcare Medical Fitness Health (all) Insu

  36. Slide 36: Pivotal trial evidence suggests BT-001 potential

    The evidence from our pivotal trial suggests that BT-001 has the potential to be… We envision As efficacious as the best available drugs • BT-001 to become Safe - with generally fewer AEs and more use • standard of care not reflecting any increased risk for most adult Impactful on several health out

  37. Slide 37: Contents

    The Problem Better Therapeutics Approach How our Product Works Contents BT-001 Pivotal Trial Go-to-Market Plan Investment Summary 37

  38. Slide 38: Platform targets prevalent and costly conditions

    Hypertension (High blood pressure) 70 million Type 2 Diabetes people suffering (High blood sugar) $30 billion 35 million people suffering Rx drug spending Our Digital $52 billion Therapeutics platform Root Causes Rx drug spending targets some of the Poor diet • Sedentary lifestyle • most prevalent a

  39. Slide 39: Path to regulatory approval and payer focus

    PATH TO REGULATORY APPROVAL We plan to focus on securing coverage from regionally dominant, early adopting commercial payers, IDNs/health systems LEADING INDICATORS OF ADOPTION: PAYERS HEALTH SYSTEMS • Population health focused • Centralized decision-making • History of adopting new • Accountable Ca

  40. Slide 40: Payer response to pivotal data

    Payers highlighted the following as meaningful and compelling • Efficacy, particularly in responders and improvement from 90 days to 180 days • Study design including patient diversity, robust treatment background, patient self selection of dose Payer response to • Patient retention at 180 days; bet

  41. Slide 41: Payer Survey

    Payer Survey National and regional payers, as well as PBMs reacted positively to BT-001’s Target Product Profile Likelihood to Cover BT-001 (n=14) 71% responded “likely to cover” 1 2 3 4 14% 14% 43% 21% 7% 5 6 7 Source: Better Therapeutics Quantitative Market Research, Feb/Mar 2022. The 1 to 7 scale

  42. Slide 42: Provider Survey

    Provider Survey Providers have expressed a willingness to prescribe BT-001 based on Target Product Profile Likelihood to Prescribe BT-001 (n=25) 88% rated “likely to prescribe” 1 2 3 4 4% 8% 12% 48% 28% 5 6 7 Source: Better Therapeutics Quantitative Market Research, Feb/Mar 2022. The 1 to 7 scale re

  43. Slide 43: Contents

    The Problem Better Therapeutics Approach How our Product Works Contents BT-001 Pivotal Trial Go-to-Market Plan Investment Summary 43

  44. Slide 44: Upcoming Milestones

    De Novo Submission Q3 2022 Upcoming Milestones Initiate payer discussions Q3 2022 Top line data from LivVita Liver Study for Q4 2022 NAFLD and NASH Q4 2022/ Address financing needs Q1 2023 Pending FDA Commercial launch Authorization Pipeline Expansion / Next Pivotal Study 2023 44

  45. Slide 45: LivVita Study top-line data expected Q4 2022

    LivVita Study Top-Line Data expected in Q4 2022 Measured at 90 Days Primary Endpoint Average change in liver fat after 90 days in participants with baseline proton density fat fraction (PDFF) ≥ 10%, as Single Arm Interventional measured by MRI-PDFF Cohort Study Patients with non-alcoholic steatohepa

  46. Slide 46: Investment in BTTX - Favorable Risk-Return Profile

    Investment in BTTX - Favorable Risk-Return Profile Potential to disrupt and create substantial value Targeting some of the largest indications in healthcare Addressing significant unmet medical needs and massive expense burdens Strong pivotal data - Impact on several health outcome measures Potentia

  47. Slide 47: Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases

    Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases

Better Therapeutics — Investor Presentation (September 2022) on 6ix